Loading stock data…
IMVT
$31.42-0.19 (-0.60%)
Market OpenUpdated 1:27 PM EDT
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunovant, Inc. in the Healthcare sector is trading at $31.42. Wall Street consensus targets $45.76 (17 analysts), implying a +45.7% move over the next 12 months. The stock is currently 13% below its 52-week high of $36.28, remaining 30.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 28) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$159.55M↓ | -$114.36M↑ | -$131.76M↓ | -$127.22M↓ | -$113.83M |
| Net Income | -$147.86M↓ | -$110.64M↑ | -$126.50M↓ | -$120.61M↓ | -$106.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating pol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.30%
Volume
Today's trading volume
531,722
Recent News
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
Clinical trial update puts IMVT-1402 in focus Recent commentary around high response rates in Immunovant (IMVT) Phase 2 rheumatoid arthritis trial, including in patients already treated with multiple advanced therapies, has drawn fresh attention to the company lead IMVT-1402 program. See our latest analysis for Immunovant. The clinical update comes against a backdrop of a firming trend in Immunovant's share price, with a 1-month share price return of 17.35%, a 3-month share price return of...
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to invest in. On May 21, H.C. Wainwright boosted Immunovant, Inc. (NASDAQ:IMVT)’s price objective to $40 from $35, keeping a Buy rating on the company’s shares. The firm noted high response rates from its Phase 2 rheumatoid arthritis trial. The trial showed that past exposure […]
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
Immunovant, Inc. (NASDAQ:IMVT) is one of the best momentum stocks to buy according to analysts. Truist lifted the price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $23 on May 22, maintaining a Hold rating on the shares. The firm told investors in a research note that it updated its model after the company reported fiscal […]
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.